Basal-cell carcinoma: Latest News, Top Stories & Analysis

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled encouraging clinical data for its investigational therapy, VP-315, at the 2025 Winter Clinical Dermatology Conference in Miami, Florida. The Phase 2 …

Cancer / Research

Verrica Pharmaceuticals Reports Promising Phase 2 Results for VP-315 in Basal Cell Carcinoma

August 15, 2024August 14, 2024 - by Timothy Alexander

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced this week that Part 2 of its Phase 2 clinical trial for VP-315, a potential first-in-class oncolytic peptide, has yielded …